Novo’s oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Avidity’s upsized $345M offering; Janus Henderson’s new $150M biotech fund

Plus, news about Phathom and CANbridge: Avidity Biosciences closes $345.1M offering: The raise comes on the heels of Phase 1/2 data … Sign up to

August 20, 2024

Bivalent COVID-19 vaccine boosts immunity but needs to be updated

A major bivalent COVID-19 vaccine induces production of neutralizing antibodies against the coronavirus that circulated at the start of the pandemic as well as subvariants

April 25, 2024

Persistent poverty and parental mental illness linked to increased risk of youth violence

Living with persistent poverty and/or parental mental illness throughout childhood may double the risk of carrying and/or using a weapon and getting on the wrong

January 22, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.